Serum KL-6 Could Represent a Reliable Indicator of Unfavourable Outcome in Patients with COVID-19 Pneumonia.
COVID-19
KL-6
SARS-CoV-2
mortality
pneumonia
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
20 02 2021
20 02 2021
Historique:
received:
14
01
2021
revised:
13
02
2021
accepted:
16
02
2021
entrez:
6
3
2021
pubmed:
7
3
2021
medline:
12
3
2021
Statut:
epublish
Résumé
KL-6 is a sialoglycoprotein antigen which proved elevated in the serum of patients with different interstitial lung diseases, especially in those with a poorer outcome. Given that interstitial pneumonia is the most common presentation of SARS-CoV2 infection, we evaluated the prognostic role of KL-6 in patients with COVID-19 pneumonia. Patients with COVID-19 pneumonia were prospectively enrolled. Blood samples were collected at the time of enrolment (TOE) and on day 7 (T1). Serum KL-6 concentrations were measured by chemiluminescence enzyme immunoassay using a KL-6 antibody kit (LUMIPULSE G1200, Fujirebio) and the cut-off value was set at >1000 U/mL. Fifteen out of 34 enrolled patients (44.1%) died. Patients with unfavourable outcome showed significantly lower P/F ratio and higher IL-6 values and plasmatic concentrations of KL-6 at TOE compared with those who survived (median KL-6: 1188 U/mL vs. 260 U/mL,
Identifiants
pubmed: 33672761
pii: ijerph18042078
doi: 10.3390/ijerph18042078
pmc: PMC7924557
pii:
doi:
Substances chimiques
Biomarkers
0
MUC1 protein, human
0
Mucin-1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Thorac Cardiovasc Surg. 2014 May;147(5):1604-1611.e3
pubmed: 24267779
J Clin Lab Anal. 2019 Oct;33(8):e22978
pubmed: 31301087
J Rheumatol. 2016 Oct;43(10):1825-1831
pubmed: 27481907
J Med Virol. 2021 Jan;93(1):158-160
pubmed: 32633842
Chest. 1992 Mar;101(3):858-60
pubmed: 1541162
Am Rev Respir Dis. 1993 Sep;148(3):637-42
pubmed: 8368634
Front Pharmacol. 2020 Sep 15;11:572870
pubmed: 33041814
J Clin Med. 2020 May 20;9(5):
pubmed: 32443899
Pulmonology. 2019 May - Jun;25(3):143-148
pubmed: 30007895
Respir Med. 2014 Jul;108(7):1031-9
pubmed: 24835074
Respir Investig. 2012 Mar;50(1):3-13
pubmed: 22554854
Respir Investig. 2017 Jan;55(1):16-23
pubmed: 28012488
J Diabetes Complications. 2002 Sep-Oct;16(5):352-8
pubmed: 12200080
Respirology. 2006 Mar;11(2):164-8
pubmed: 16548901
Chest. 1996 May;109(5):1276-82
pubmed: 8625680
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Daru. 2020 Dec;28(2):807-812
pubmed: 32851596
BMJ Open. 2012 May 15;2(3):
pubmed: 22587885
Am J Respir Crit Care Med. 1998 Oct;158(4):1294-8
pubmed: 9769294
Biosci Trends. 2020 Sep 21;14(4):290-296
pubmed: 32565512
Am J Physiol Lung Cell Mol Physiol. 2004 Jun;286(6):L1088-94
pubmed: 12959931
Clin Infect Dis. 2020 Nov 19;71(16):2174-2179
pubmed: 32445579
Intern Emerg Med. 2021 Jan 16;:
pubmed: 33453011
Arthritis Res Ther. 2019 Feb 14;21(1):58
pubmed: 30764869
Chest. 1995 Aug;108(2):311-5
pubmed: 7634858
J Med Virol. 2020 Oct;92(10):2216-2220
pubmed: 32470148
J Med Invest. 1999 Aug;46(3-4):151-8
pubmed: 10687309
J Clin Virol. 2020 Jun;127:104370
pubmed: 32344321
Respirology. 2002 Mar;7(1):15-21
pubmed: 11896896
Am J Respir Crit Care Med. 1997 Jul;156(1):109-15
pubmed: 9230733
Respir Res. 2011 Mar 22;12:32
pubmed: 21418654
Int J Cancer Suppl. 1994;8:81-3
pubmed: 8194900
Eur Respir J. 2004 Jan;23(1):142-5
pubmed: 14738246
Dis Markers. 2016;2016:4759040
pubmed: 27293304
J Intern Med. 2006 Nov;260(5):429-34
pubmed: 17040248
Clin Cancer Res. 2000 Oct;6(10):4069-72
pubmed: 11051258